Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Hematologic Malignancies

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1661036

The Prognostic Significance of Incomplete Hematological Recovery in Pediatric Patients with Low/Intermediate Risk AML and Negative MRD after Induction 1

Provisionally accepted
Nessma  ShahinNessma Shahin1*Mahmoud  HammadMahmoud Hammad2*hanafy  hafezhanafy hafez2sherine  salemsherine salem1,2nahla  elsharkawynahla elsharkawy1,2amr  elnasharamr elnashar3Leslie  LehmannLeslie Lehmann4Alaa  ElhaddadAlaa Elhaddad1,2
  • 1Children’s Cancer Hospital (Egypt), Zenab, Egypt
  • 2National Cancer Institute Cairo University, Cairo, Egypt
  • 3Ain Shams University, Cairo, Egypt
  • 4Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, United States

The final, formatted version of the article will be published soon.

Background: Pediatric (AML) accounts for approximately 25% of childhood hematologic malignancies. Outcomes have markedly improved, especially in low-risk and intermediate-risk patients, with overall survival (OS) rates approaching 80–85%. Prognosis is primarily determined by cytogenetic/molecular risk and minimal residual disease (MRD) status following induction therapy. While complete remission (CR) traditionally requires morphologic clearance of leukemia with full hematologic recovery, some patients achieve morphologic remission with incomplete recovery (CRi). Although adult studies associate CRi with poor prognosis, its relevance in MRD-negative pediatric AML remains unclear. This study evaluates the prognostic significance of hematologic recovery in MRD-negative, low/intermediate-risk pediatric AML. Methods: We conducted a retrospective analysis of 120 pediatric AML patients treated at CCHE-57357 between 2012 and 2020 who achieved MRD negativity (<0.1% by 8–10 color flow cytometry) after Induction I. Risk stratification followed WHO/ELN guidelines. For exploratory purposes, intermediate-risk patients with MRD <0.1% were reclassified as "MRD-defined low risk." Patients were categorized by hematologic recovery: CR (ANC ≥1000/µL, platelets ≥100,000/µL), partial hematological recovery (CRh ) (ANC ≥500/µL and/or platelets ≥50,000/µL), and CRi (ANC 500/µL and/or platelets <50,000/µL). Outcomes included OS, relapse-free survival (RFS), and event-free survival (EFS). Results: Among 120 patients (median age 8.5 years), 25 (21%) achieved CR, 17 (14.3%) CRh, and 78 (64.7%) CRi. CRi patients had numerically lower 5-year OS (63.3%) compared to CRh (76%) and CR (71.8%), though differences were not statistically significant. Platelet recovery alone ( complete Platelet recovery ( CRp) vs incomplete platelet recovery (CRip) showed a trend toward prognostic relevance (5-year OS: 73.3% vs 57.1%), also non-significant. Infectious complications were common: six sepsis-related deaths occurred in the low-risk group and four in the standard-risk group, with ICU admissions disproportionately higher in standard-risk patients (12 vs 1). CRi patients experienced longer hospital stays and required more transfusion support. Conclusion: In MRD-negative pediatric AML, incomplete hematologic recovery did not significantly predict inferior survival, though trends suggest potential prognostic value—particularly in low-risk patients. CRi may reflect treatment-related toxicity or infectious complications rather than residual disease. These findings support a more nuanced interpretation of remission depth and highlight the need for multi-institutional studies incorporating molecular risk refinement

Keywords: Pediatric acute myeloid leukemia (AML ), Minimal residual disease (MRD ), Complete remission (CR ), Incomplete remission (CRi), Morphological remission

Received: 07 Jul 2025; Accepted: 30 Sep 2025.

Copyright: © 2025 Shahin, Hammad, hafez, salem, elsharkawy, elnashar, Lehmann and Elhaddad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Nessma Shahin, nessma.mahmoud@57357.org
Mahmoud Hammad, mahmoud.hammad@nci.cu.edu.eg

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.